Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OB 002

Next Previous
Drug Profile

OB 002

Alternative Names: 5P12-RANTES; 5P12-RANTES-E66S; OB 002; OB-002C; OB-002H; OB-002M; OB-002O

Latest Information Update: 21 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Mintaka Foundation for Medical Research
  • Developer Orion Biotechnology Canada; Queens University Belfast; The Mintaka Foundation for Medical Research
  • Class Antineoplastics; Antiretrovirals; Antivirals; Chemokines; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer
  • No development reported Breast cancer; Gastrointestinal cancer; HIV infections; Multiple sclerosis; Stroke

Most Recent Events

  • 09 Apr 2025 Orion Biotechnology withdrawn phase I trial prior to enrollment for Cancer (Metastatic disease) before April 2025 (NCT05940844)
  • 27 Mar 2024 OB 002 is still in preclinical development in Colorectal-cancer in Switzerland (IV) (Orion Biotechnology pipeline, March 2024)
  • 28 Nov 2023 No recent reports of development identified for preclinical development in Breast-cancer(Metastatic disease) in Canada (Intraperitoneal, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top